Kivexa Tablets

Adult dose

This medicine should be prescribed by a physician experienced in the treatment of HIV infection and may be administered with or without food. This medicine is a fixed-dose tablet and should not be prescribed to patients who require dose adjustment. If dose adjustment or discontinuation of one of the ingredients is necessary, abacavir or lamivudine may be prescribed separately; in such cases, the physician should refer to the prescribing information for the individual products. Adults and adolescents: The recommended dose is 1 tablet once daily. Patients with renal impairment: This medicine is not recommended for patients with a creatinine clearance below 30ml/min, because the required dose adjustment cannot be made. Patients with hepatic impairment: Abacavir is primarily metabolized in the liver. Use should be avoided in patients with moderate or severe hepatic impairment because there are insufficient data to support a dose. If abacavir is administered to patients with mild hepatic impairment (Child-Pugh score 5-6), careful monitoring is required, including monitoring of abacavir plasma concentrations where possible.

Child dose

Pediatric patients weighing 25kg or more: The recommended dose is 1 tablet once daily. Pediatric patients weighing less than 25kg: This medicine should not be administered to pediatric patients weighing less than 25kg because it is a fixed-dose tablet that cannot be reduced.

This medication can cause hypersensitivity reactions, so if symptoms such as fever or rash occur, it should be discontinued immediately. The risk of hypersensitivity is particularly high in patients with certain genetic traits, so genetic testing should be considered before taking this medication. During treatment with this medication, patients should closely monitor for any symptoms of hypersensitivity and consult healthcare professionals immediately if suspected. Hypersensitivity can be life-threatening, so it is important to stop the medication without delay if symptoms occur. Additionally, this medication should not be administered to patients with severe liver and kidney function impairment, and it should be used cautiously in patients at risk of hepatic disease or lactic acidosis. The safety of this medication has not been established during pregnancy, so pregnant women should determine use after consultation with their doctors, and breastfeeding women should avoid nursing while taking this medication. Regular tests for liver function, blood counts, kidney function, etc., should be conducted during treatment to check for adverse reactions, and any abnormal symptoms should be reported to healthcare professionals immediately. Caution should be taken while driving or operating machinery during treatment, and potential interactions with alcohol or certain medications should be discussed with healthcare professionals regarding any concurrent medications. No specific symptoms are known for overdose; however, if suspected, it is important to visit a medical facility immediately for appropriate treatment. Finally, this medication should be stored out of reach of children, and it is safest not to transfer it into other containers.

• Allergic reactions
• fever
• rash
• pneumonia
• bronchitis
• pharyngitis
• gastroenteritis
• nausea
• vomiting
• diarrhea

This medication should be stored in a tightly closed container to prevent exposure to air and moisture. It is best to store it at room temperature between 1 to 30 degrees Celsius and not in excessively cold or hot places.

Appearance

Orange rectangular film-coated tablets

Package unit

30 tablets (10 tablets/PTP X 3)